Papers/PMID:22124575
Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2012The record
2 findings · 1 compound · 2 endpoints
What it reported
How to read these marksWhat moved
2 findings
strontium(2+) — decreases vertebral fracture incidence
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.Findingreplicated ×2“The cumulative incidence of new vertebral fractures in the 10-year population in years 6 to 10 was significantly lower than that observed over 5 years in the FRAX®-matched placebo population (20.6 ± 3.0% versus 28.2 ± 2.4%, respectively; relative reduction in risk [RRR] 35%, P = 0.016).”
Quoted verbatim from Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.. - Study
- cohort
- Dose
- strontium ranelate 2 g/day
- Population
- Postmenopausal women with osteoporosis who took strontium ranelate for up to 10 years in the open-label extension of SOTI and TROPOS (the 10-year population, completers only), compared in years 6 to 10 with a FRAX-matched placebo group drawn from the TROPOS placebo arm over years 0 to 5; calcium and vitamin D given
Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.2012PMID:22124575Permalink
strontium(2+) — decreases non-vertebral fracture incidence
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.Findingreplicated ×1“Similarly, the 10-year population had significantly lower rates of nonvertebral fracture and new osteoporotic fracture in years 6 to 10 than the FRAX®-matched placebo population over 5 years (nonvertebral fracture: 13.7 ± 2.3% versus 20.2 ± 2.2%, respectively, RRR 38%, P = 0.023; new osteoporotic fracture: 30.3 ± 3.1% versus 39.2 ± 2.5%, RRR 30%, P = 0.012).”
Quoted verbatim from Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.. - Study
- cohort
- Dose
- strontium ranelate 2 g/day
- Population
- Postmenopausal women with osteoporosis who took strontium ranelate for up to 10 years in the open-label extension of SOTI and TROPOS (the 10-year population, completers only), compared in years 6 to 10 with a FRAX-matched placebo group drawn from the TROPOS placebo arm over years 0 to 5; calcium and vitamin D given
Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.2012PMID:22124575Permalink